 | ||
Foretinib gsk1363089 is an atp competitive inhibitor
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued.
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).
References
Foretinib Wikipedia(Text) CC BY-SA